Compare ASC & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | DNA |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | Bermuda | United States |
| Employees | N/A | 485 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.9M | 599.0M |
| IPO Year | 2013 | N/A |
| Metric | ASC | DNA |
|---|---|---|
| Price | $16.88 | $9.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.00 | $8.50 |
| AVG Volume (30 Days) | 500.1K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.53 | $5.37 |
| 52 Week High | $20.03 | $17.58 |
| Indicator | ASC | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 59.00 |
| Support Level | $14.91 | $7.59 |
| Resistance Level | $20.03 | $10.27 |
| Average True Range (ATR) | 0.62 | 0.74 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 89.36 | 53.10 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.